Novo Holdings A/S’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Novo Holdings A/S’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,836	Closed	-$3.27M	–	20
2017 Q2	$3.27M	Sell	6,836 -276	-4%	-$209K	0.39%	20
2017 Q1	$8.86M	Hold	7,112	–	–	0.94%	18
2016 Q4	$2.87M	Hold	7,112	–	–	0.27%	20
2016 Q3	$2.91M	Hold	7,112	–	–	0.26%	15
2016 Q2	$3.48M	Hold	7,112	–	–	0.37%	16
2016 Q1	$3.67M	Hold	7,112	–	–	0.4%	13
2015 Q4	$5.58M	Hold	7,112	–	–	0.54%	10
2015 Q3	$9.76M	Hold	7,112	–	–	1.01%	15
2015 Q2	$14.3M	Buy	+7,112	New	+$18.2M	1.03%	15

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Novo Holdings A/S's HTGM Position: Q3 2017 in Review

Novo Holdings A/S sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2017, closing a stake of 6,836 shares — an estimated $3.27M sold.

Novo Holdings A/S first reported a position in HTGM in Q2 2015 and held it in 9 quarters. The position peaked at $14.3M in Q2 2015. 21 funds tracked by Wall St. Rank hold HTGM as of Q3 2017.

Novo Holdings A/S reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Novo Holdings A/S sold 6,836 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2017, an estimated $3.27M.
Novo Holdings A/S first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 9 quarters.
Novo Holdings A/S's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $14.3M in Q2 2015.
21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2017.

Based on Novo Holdings A/S's 13F filing for Q3 2017, filed 14 Nov 2017.